+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cell Reprogramming Market Research Report by Technology (Episomal Reprogramming, mRNA Reprogramming, and Sendai Virus-Based Reprogramming), Application, End-Use, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 256 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5715495
UP TO OFF until Mar 31st 2023
The Global Cell Reprogramming Market size was estimated at USD 341.23 million in 2022, USD 375.59 million in 2023, and is projected to grow at a CAGR of 10.52% to reach USD 759.92 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Cell Reprogramming Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Cell Reprogramming Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Cell Reprogramming Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Cell Reprogramming Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Cell Reprogramming Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Technology, the market is studied across Episomal Reprogramming, mRNA Reprogramming, and Sendai Virus-Based Reprogramming.
  • Based on Application, the market is studied across Research and Therapeutic.
  • Based on End-Use, the market is studied across Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, and Research & Academic Institutes.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Cell Reprogramming Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Cell Reprogramming Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Cell Reprogramming Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Cell Reprogramming Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Reprogramming Market, including Advanced Cell Technology Inc., Allele Biotechnology and Pharmaceuticals Inc., ALSTEM Inc., Applied Biological Materials Inc., Axol Bioscience Ltd., Bristol Myers Squibb Company, Creative Bioarray, DefiniGEN Limited, Fujifilm Cellular Dynamics, Inc., Lonza AG, Merck KGaA, Mogrify Limited, REPROCELL Inc., Stemnovate Limited, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cell Reprogramming Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cell Reprogramming Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cell Reprogramming Market?
4. What is the competitive strategic window for opportunities in the Global Cell Reprogramming Market?
5. What are the technology trends and regulatory frameworks in the Global Cell Reprogramming Market?
6. What is the market share of the leading vendors in the Global Cell Reprogramming Market?
7. What modes and strategic moves are considered suitable for entering the Global Cell Reprogramming Market?
Frequently Asked Questions about the Global Cell Reprogramming Market

What is the estimated value of the Global Cell Reprogramming Market?

The Global Cell Reprogramming Market was estimated to be valued at $341.23 Million in 2022.

What is the growth rate of the Global Cell Reprogramming Market?

The growth rate of the Global Cell Reprogramming Market is 10.5%, with an estimated value of $759.92 Million by 2030.

What is the forecasted size of the Global Cell Reprogramming Market?

The Global Cell Reprogramming Market is estimated to be worth $759.92 Million by 2030.

Who are the key companies in the Global Cell Reprogramming Market?

Key companies in the Global Cell Reprogramming Market include Advanced Cell Technology Inc., Allele Biotechnology and Pharmaceuticals Inc., ALSTEM Inc., Applied Biological Materials Inc., Axol Bioscience Ltd., Bristol Myers Squibb Company, Creative Bioarray, DefiniGEN Limited and Lonza AG.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing interest of scientists and researchers in the field of human cell development
5.1.1.2. Rising investment and funding from government and biotechnology and biopharmaceutical companies for cell-based research
5.1.1.3. Growing awareness among people regarding stem cell and cellular reprogramming
5.1.2. Restraints
5.1.2.1. High cost of cell reprogramming
5.1.3. Opportunities
5.1.3.1. Growing investments to launch advanced cell reprogramming
5.1.3.2. Research and development in advanced cell reprogramming
5.1.3.3. Rising research outsourcing by pharmaceutical companies
5.1.4. Challenges
5.1.4.1. Lack of awareness regarding benefits of cell reprogramming
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Cell Reprogramming Market, by Technology
6.1. Introduction
6.2. Episomal Reprogramming
6.3. mRNA Reprogramming
6.4. Sendai Virus-Based Reprogramming

7. Cell Reprogramming Market, by Application
7.1. Introduction
7.2. Research
7.3. Therapeutic

8. Cell Reprogramming Market, by End-Use
8.1. Introduction
8.2. Biotechnology & Pharmaceutical Companies
8.3. Hospitals & Clinics
8.4. Research & Academic Institutes

9. Americas Cell Reprogramming Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Cell Reprogramming Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Cell Reprogramming Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Product Portfolio Analysis, By Key Player
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Advanced Cell Technology Inc.
13.2. Allele Biotechnology and Pharmaceuticals Inc.
13.3. ALSTEM Inc.
13.4. Applied Biological Materials Inc.
13.5. Axol Bioscience Ltd.
13.6. Bristol Myers Squibb Company
13.7. Creative Bioarray
13.8. DefiniGEN Limited
13.9. Fujifilm Cellular Dynamics, Inc.
13.10. Lonza AG
13.11. Merck KGaA
13.12. Mogrify Limited
13.13. REPROCELL Inc.
13.14. Stemnovate Limited
13.15. Thermo Fisher Scientific, Inc.

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing


List of Figures
FIGURE 1. GLOBAL CELL REPROGRAMMING MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL CELL REPROGRAMMING MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CELL REPROGRAMMING MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CELL REPROGRAMMING MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL CELL REPROGRAMMING MARKET DYNAMICS
FIGURE 11. GLOBAL CELL REPROGRAMMING MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 13. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL CELL REPROGRAMMING MARKET COMPETITIVE STRATEGIC WINDOW, BY TECHNOLOGY, 2030
FIGURE 15. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY EPISOMAL REPROGRAMMING, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY MRNA REPROGRAMMING, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY SENDAI VIRUS-BASED REPROGRAMMING, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 19. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL CELL REPROGRAMMING MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2030
FIGURE 21. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
FIGURE 22. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2022 VS 2030 (%)
FIGURE 24. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL CELL REPROGRAMMING MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USE, 2030
FIGURE 26. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
FIGURE 27. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
FIGURE 28. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
FIGURE 29. AMERICAS CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 30. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 31. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 32. AMERICAS CELL REPROGRAMMING MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 33. ARGENTINA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 34. BRAZIL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 35. CANADA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 36. MEXICO CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 37. UNITED STATES CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 38. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 39. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 40. UNITED STATES CELL REPROGRAMMING MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 41. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 43. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 44. ASIA-PACIFIC CELL REPROGRAMMING MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 45. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 46. CHINA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 47. INDIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. INDONESIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. JAPAN CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. MALAYSIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. SINGAPORE CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. TAIWAN CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. THAILAND CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. VIETNAM CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 61. DENMARK CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 62. EGYPT CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. FINLAND CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. FRANCE CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. GERMANY CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. ISRAEL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. ITALY CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. NIGERIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. NORWAY CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. POLAND CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. QATAR CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. RUSSIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. SPAIN CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. SWEDEN CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. TURKEY CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 81. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 82. GLOBAL CELL REPROGRAMMING MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 83. GLOBAL CELL REPROGRAMMING MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 84. GLOBAL CELL REPROGRAMMING MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL CELL REPROGRAMMING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY EPISOMAL REPROGRAMMING, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY EPISOMAL REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY EPISOMAL REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY MRNA REPROGRAMMING, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY MRNA REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY MRNA REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY SENDAI VIRUS-BASED REPROGRAMMING, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY SENDAI VIRUS-BASED REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY SENDAI VIRUS-BASED REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 46. CANADA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 47. CANADA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 48. CANADA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 50. MEXICO CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 52. MEXICO CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. MEXICO CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 68. CHINA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 69. CHINA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 70. CHINA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. CHINA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 72. INDIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 73. INDIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. INDIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. INDIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 80. JAPAN CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 81. JAPAN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 82. JAPAN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. JAPAN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 84. MALAYSIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 85. MALAYSIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. MALAYSIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. MALAYSIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 88. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 89. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 90. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 92. SINGAPORE CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 93. SINGAPORE CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. SINGAPORE CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. SINGAPORE CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 96. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 97. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 98. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 100. TAIWAN CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 101. TAIWAN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 102. TAIWAN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. TAIWAN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 104. THAILAND CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 105. THAILAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. THAILAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. THAILAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 108. VIETNAM CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 109. VIETNAM CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. VIETNAM CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. VIETNAM CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 117. DENMARK CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 118. DENMARK CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. DENMARK CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. DENMARK CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 121. EGYPT CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 122. EGYPT CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 123. EGYPT CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. EGYPT CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 125. FINLAND CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 126. FINLAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 127. FINLAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. FINLAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 130. FRANCE CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. FRANCE CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. FRANCE CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 133. GERMANY CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 134. GERMANY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 135. GERMANY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. GERMANY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 137. ISRAEL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 138. ISRAEL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 139. ISRAEL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. ISRAEL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 141. ITALY CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 142. ITALY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 143. ITALY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. ITALY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 145. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 146. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 147. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 149. NIGERIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 150. NIGERIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 151. NIGERIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. NIGERIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 153. NORWAY CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 154. NORWAY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. NORWAY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. NORWAY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 157. POLAND CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 158. POLAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 159. POLAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. POLAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 161. QATAR CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 162. QATAR CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 163. QATAR CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. QATAR CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 174. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 177. SPAIN CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 178. SPAIN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 179. SPAIN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. SPAIN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 185. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 186. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 189. TURKEY CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 190. TURKEY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. TURKEY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. TURKEY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 201. GLOBAL CELL REPROGRAMMING MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 202. GLOBAL CELL REPROGRAMMING MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 203. GLOBAL CELL REPROGRAMMING MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 204. GLOBAL CELL REPROGRAMMING MARKET RANKING, BY KEY PLAYER, 2022
TABLE 205. GLOBAL CELL REPROGRAMMING MARKET SHARE, BY KEY PLAYER, 2022
TABLE 206. GLOBAL CELL REPROGRAMMING MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 207. GLOBAL CELL REPROGRAMMING MARKET MERGER & ACQUISITION
TABLE 208. GLOBAL CELL REPROGRAMMING MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 209. GLOBAL CELL REPROGRAMMING MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 210. GLOBAL CELL REPROGRAMMING MARKET INVESTMENT & FUNDING
TABLE 211. GLOBAL CELL REPROGRAMMING MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 212. GLOBAL CELL REPROGRAMMING MARKET: LICENSE & PRICING

Companies Mentioned

  • Advanced Cell Technology Inc.
  • Allele Biotechnology and Pharmaceuticals Inc.
  • ALSTEM Inc.
  • Applied Biological Materials Inc.
  • Axol Bioscience Ltd.
  • Bristol Myers Squibb Company
  • Creative Bioarray
  • DefiniGEN Limited
  • Fujifilm Cellular Dynamics, Inc.
  • Lonza AG
  • Merck KGaA
  • Mogrify Limited
  • REPROCELL Inc.
  • Stemnovate Limited
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...